NYT notes health effects with puberty blockers, and Reuters reports on the disparity between number of girls vs boys undergoing treatment.
I recently described, in detail, the side effects associated with endocrine-disrupting puberty blockers that are being used on children undergoing transgender medical treatments.
My colleague, New Neo, also reported that the United Kingdom’s National Health Service was rethinking policies related to providing these drugs to British kids. The new policies will place restrictions on puberty blockers. Additionally, medical doctors, not therapists, will be expected to lead the provision of transgender services.
Finally, the mainstream media may now be gender-transitioning questioning. The New York Times recently published a rather lengthy piece on the health effects of puberty blockers when used on children.
…[A]as an increasing number of adolescents identify as transgender — in the United States, an estimated 300,000 ages 13 to 17 and an untold number who are younger — concerns are growing among some medical professionals about the consequences of the drugs, a New York Times examination found. The questions are fueling government reviews in Europe, prompting a push for more research and leading some prominent specialists to reconsider at what age to prescribe them and for how long. A small number of doctors won’t recommend them at all.
Dutch doctors first offered puberty blockers to transgender adolescents three decades ago, typically following up with hormone treatment to help patients transition. Since then, the practice has spread to other countries, with varying protocols, little documentation of outcomes and no government approval of the drugs for that use, including by the U.S. Food and Drug Administration.
But there is emerging evidence of potential harm from using blockers, according to reviews of scientific papers and interviews with more than 50 doctors and academic experts around the world.
The drugs suppress estrogen and testosterone, hormones that help develop the reproductive system but also affect the bones, the brain and other parts of the body. [hat-tip, Ace of Spades HQ]
Additionally, Reuters just published a piece focusing in the disparity between the number of females transitioning to the number of males doing so.
Thousands of children who, like Kulovitz, were assigned female at birth have sought gender-affirming care in recent years. And for reasons not well-understood, they significantly outnumber those assigned male at birth who seek treatment.
As Reuters reported in October, a growing number of the children receiving care at the 100-plus gender clinics across the United States are opting for medical interventions – puberty-blocking drugs, hormones and, less often, surgery. And they are doing so even though strong scientific evidence of the long-term safety and efficacy of these treatments for children is scant.
That has led to a split among gender-care specialists: those who urge caution to ensure that only adolescents deemed well-suited to treatment after thorough evaluation receive it, and those who believe that delays in treatment unnecessarily prolong a child’s distress and put them at risk of self-harm.
The outsized proportion of adolescents seeking treatment to transition from female to male has sparked parallel concerns. Professionals in the gender-care community agree that treatment of all transgender children should be supportive and affirming. The question, for some, is whether peer groups and online media may be influencing some of these patients to pursue medical transition, with potentially irreversible side effects, at a time in their lives when their identities are often in flux.
The science, truthfully presented, coupled with a few lawsuits should stop these medical travesties.DONATE
Donations tax deductible
to the full extent allowed by law.